Date: Monday, November 4, 2013, 7:30AM-8:30AM

Co-Chairs:
Bruce Crawford, 2012-2014 Chair, ISPOR Asia Consortium Education Committee
Donald Yin, 2012-2014 Chair-Elect, ISPOR Asia Consortium Health Technology Producers (Industry) Committee

Participants (46 in total):
Meeting attendees: (see the attendee list in page 4-5)
Asia Consortium Executive Committee members: Shanlian Hu, Isao Kamae, Kenneth KC Lee, Vivian Lee, Alexandr Kostyuk, and Bongmin Yang
Guests of Honor: William H. Crown, 2013-2014 ISPOR President and Marilyn Dix Smith, ISPOR Founding Executive Director
ISPOR Staff: Robert Selby and Zandra Yin

Objective:
The objective of this meeting is to share recent initiatives within ISPOR Asia Consortium and health policy developments in Asia.

Proceedings:
I. Welcome and opening remarks
1. Meeting Chairs Bruce Crawford and Donald Yin opened the meeting by welcoming the ISPOR Founding Executive Director Marilyn Dix Smith and thanking her for her extraordinary leadership of ISPOR and ISPOR Asia Consortium. Under Dr. Smith’s guidance the Asia Consortium has grown to over 600 members with representation from 24 ISPOR Regional Chapters in Asia.
2. ISPOR Founding Executive Director Marilyn Dix Smith welcomed the attendees to the Asia Consortium meeting and thanked them for their support. Dr. Smith particularly mentioned that due to consortium members’ effort, ISPOR Asia Consortium has grown into a dynamic group that has 8 active working committees, co-organizes biennial ISPOR Asia-Pacific Conferences and puts out key publications such as Value in Health Regional Issues and News Across Asia.
3. ISPOR 2013-2014 President William Crown delivered welcome remarks to the attendees, noting that the emerging regions, and particularly Asia, will play an ever more important role in the development and advancement of pharmacoeconomics and outcomes research. Dr. Crown also encouraged attendees to participate in the ISPOR 6th Asia-Pacific Conference in Beijing, China, 6-9 September 2014.

II. Brief Report on the Consortium policy changes
ISPOR Board of Directors member Kenneth KC Lee, on behalf of Surachat Ngorsuraches, 2012-2014 Chair of the ISPOR Asia Consortium Executive Committee, presented the ISPOR Board of Directors’ approval of the following policy changes to the ISPOR regional consortia that will take effect for the Asia Consortium immediately.
1. Two Working Committees – the HTA Agencies Committee and the Health Care Policymakers & Payers Committee - will be combined into one committee, the Asia Consortium HTA Agencies, Policymakers & Payers Committee, to provide a more effective communication platform for health technology assessors and health care decision makers in Asia.
2. HTAnetAsia, the HTA network of ISPOR Asia Consortium, will be formally grafted into the Consortium structure to support a more effective collaboration among HTA organizations conducting health technology assessment for government and private health insurance payers in Asia.

3. The Value in Health Regional Issues (ViHRI) Editorial Board for Asia will be formally included as a committee within the consortium structure to better assure a regional perspective of the journal.

4. A subcommittee within the Asia-Pacific Conference Program Committee - the Health Care Decision Maker Case Study Review Committee - will be discontinued due to too few case study abstract submissions in the past years.

Value in Health Regional Issues Co-Editor-in-Chief (Asia) Bong-Min Yang presented the ISPOR Board of Directors’ approval of transitioning the Value in Health Regional Issues (ViHRI) to an article-based online only publication which will take effect in 2014.

1. With the online publication, an article can be published immediately upon acceptance with a full citation instead of a DOI.

2. The ViHRI focusing on Asia to be published in May 2014 will become the first online issue. Manuscripts for this issue are undergoing editorial reviews, with over 65 received. Based on the previous issue published in May 2013, the rejection rate will be at nearly 70%.

3. The ViHRI Editorial Board is aiming to apply to be Medline-indexed in 2014 when each of the three regions (Asia, LA and CEEWAA) has two-three issues completed.

III. Asia Consortium recent activities
1. ISPOR Asia HTA Roundtable: The HTA roundtable “Sharing Health Technology Assessment Information Across Asia” was held on 4-5 October, 2013 in Makati City, Philippines. HTA assessors and health care decision makers from Mainland China, India, Indonesia, Japan, South Korea, Malaysia, Philippines, Taiwan, UK, EUnetHTA and WHO Asia regional offices were in attendance to share information and experiences from their respective countries/organizations. Delegates also reviewed and discussed the ISPOR Asia Consortium HTA Principles Survey result. An ISPOR website-based information sharing system SharePoint was also presented, through which the HTA resource and information will be shared among the roundtable delegates. The next ISPOR Asia HTA roundtable will be held during the ISPOR 6th Asia-Pacific Conference in Beijing, China, 6-9 September 2014.

2. ISPOR Asia-Pacific Conference 10th Anniversary Meeting: Founding members of the ISPOR Asia Consortium gathered in Kobe, Japan on October 22, 2013 to commemorate the 10th anniversary of the ISPOR 1st Asia-Pacific Conference that was held in September 2003, Kobe, Japan as well as discuss the ISPOR Asia Vision 2020, emphasizing the need for greater collaboration with other agencies such as the WHO Asia regional offices, procuring new sources of funding and directing new task force initiatives in Asia.

3. ISPOR 6th Asia-Pacific Conference: The upcoming ISPOR Asia-Pacific Conference, scheduled for 6-9 September 2014 in Beijing, China, completed its Call for Abstracts, and the conference theme, short course curriculum and plenary session topics have been chosen. The Conference has been extended by an additional 1.5 days to allow for an expanded short course and scientific program. The conference venue will be the Beijing International Conference Center.

(More information about Asia Consortium activities is available at http://www.ispor.org/consortiums/asia.asp.)

IV. Regional Chapter activity updates
1. **HTA and its Values of Medicine**: The 6th Huaxia forum, organized by the ISPOR Hong Kong Chapter, will take place in Hong Kong from April 26-27, 2014. Asia Consortium members are welcome to contact the chapter (http://www.ispor.org/regional_chapters/hongkong/index.asp) for more information.

2. **CEA in Japan**: The implementation of HTA into Japan’s health care system is still undergoing rigorous debate at the special committee level, with new decisions expected to be initiated in spring 2014.

3. **Pharmacoeconomics in Healthcare Transformation: Towards Universal Coverage**: MYSPOR, the ISPOR Malaysia Chapter, will be holding its second biennial PE Conference from 7-9 March, 2014. Asia Consortium members are welcome to contact the chapter (http://www.ispor.org/regional_chapters/Malaysia/index.asp) for more information.

4. **Generics Pricing in Australia policy directions**: The ISPOR Australia Chapter hosted a workshop on Friday, 8 November 2013.

5. **Pharmacoeconomics Guidelines for India**: the ISPOR India Chapter held the 2nd International Conference on 9-10 October 2013. During the conference, the Proposed Pharmacoeconomics Guidelines for India was presented. More information is available on the chapter webpage at http://www.ispor.org/regional_chapters/India/index.asp.

* The information was obtained before the meeting.

**Follow up actions (November 2013-March 2014):**

1. Asia Consortium working committees are to provide comments on the drafted India PE guidelines.
2. Asia Consortium leadership is to further discuss the consortium Vision 2020 and collect comments from the consortium members.
3. Asia Consortium Education Committee subcommittee Asia-Pacific Conference Short Course Committee will recommend and select instructors of the short courses to be offered during the ISPOR 6th Asia-Pacific Conference.
4. Asia-Pacific Conference Program Committee is to begin the process for nominating and selecting plenary speakers for ISPOR 6th Asia-Pacific Conference.
5. ISPOR Asia Consortium working committees/chapters will discuss and select Asia Consortium forum topics to be organized at the ISPOR 6th Asia-Pacific Conference.
6. Asia Consortium working committees/chapters are to plan group meetings to be held at the ISPOR 6th Asia-Pacific Conference.
7. Asia Consortium HTA Agencies, Health Care Policymakers & Payers Committee is to plan the HTAnetAsia Roundtable to be held during the ISPOR 6th Asia-Pacific Conference.
ISPOR Asia Consortium Business Meeting during the ISPOR 16th European Congress, Dublin, Ireland

Attendee List by Country/Region (as per sign-in/RSVP*)

*Five members in the list below were not able to attend the meeting although they RSVPed.

Australia (5)
Jason Gordon, BEc, PhD, University of Adelaide/HEOR Consulting, Adelaide, Australia
Peggy McBride, PhD, Consultant, Medtronic, North Ryde, Australia
William Montgomery, RPh, Eli Lilly, West Ryde, NSW, Australia
Adele Weston, PhD, Executive Vice President/Senior Scientist, Optum, Lilyfield, Australia
Michael Wonder, BSc, Managing Director, Wonder Drug Consulting Pty Ltd., Cronulla, NSW, Australia

China (9)
Chieh-I (JE) Chen, MPH, Associate Director, Pfizer Inc., Beijing, China
Yixi Emily Chen, Outcomes Research Specialist, Pfizer Inc., Beijing, China
Peng Dong, PhD, Associate Director of HEOR, Sanofi, Beijing, China
Shanlian Hu, MD, MSc, Associate Professor, Fudan University, Shanghai, China
Vivian Lee, PharmD, Associate Professor, Chinese University of Hong Kong, Shatin, N.T., Hong Kong, China
Qiang Shi, MD, PhD, Epidemiology Advisor, Pfizer China, Shanghai, China
Carlos Wong, Mphil, PhD, Post-doctoral Fellow, University of Hong Kong, Hong Kong, China
Xingxing Yao, MS, Student, Tianjin University, Tianjin, China
Joyce You, PharmD, Associate Professor, Chinese University of Hong Kong, Hong Kong, China

India (3)
Shaantanu Donde, Senior Manager, Medical and Research Division, Pfizer Ltd., Mumbai, India
Sunita Nair, PhD, Lead, Knowledge Services, Capita India, Mumbai, India
Bhrugu Pariti, Manipal University, Udupi, KA, India

Japan (10)
Bruce Crawford, MA, MPH, Managing Director, Asia/Senior Vice President, Adelphi Values, Tokyo, Japan
Takashi Fukuda, PhD, Chief Senior Researcher, National Institute of Public Health, Saitama, Japan
Chisato Hamashima, DrPH, MD, Section Head, National Cancer Center, Tokyo, Japan
Isao Kamae, DrPH, Professor of Health Technology Assessment, University of Tokyo, Tokyo, Japan
Makoto Kobayashi, PhD, Director, CRECON Research and Consulting Inc., Tokyo, Japan
Kazuhiro Nakamura, BS, Ritsumeikan University, Kusatsu, Japan
Shinya Saito, MD, PhD, Professor, Okayama University, Okayama, Japan
Kojo Hiro Shimozuma, MD, PhD, Professor, Ritsumeikan University, Kusatsu, Japan
Naoko Tomita, MA, Senior Researcher, National Institute of Public Health, Saitama, Japan
Yuji Yamamoto, MBA, MD, CEO & Founder, MinaCare Co., Ltd., Tokyo, Japan

Kazakhstan (1)
Alexandr Kostyuk, PhD, Professor, Department of Clinical Pharmacology & Pharmacotherapy, Head of Department for International Collaboration, Astana Medical University, Astana, Kazakhstan

Korea, South (4)
Seungjin Bae, PhD, Assistant Professor, Ewha Womans University, Seoul, South Korea
Gyoungmin Ko, BA, Deputy Director, Astellas Korea, Seoul, South Korea
Eui-kyung Lee, PhD, Professor, Sungkyunkwan University, Suwon, South Korea  
Bong-Min Yang, PhD, Professor of Health Economics, Seoul National University, Seoul, South Korea  

Malaysia (4)  
Soraya Azmi, MD, MPH, Managing Director, Azmi Burhani Consulting, Petaling Jaya, Malaysia  
Kenneth Lee, Mphil, PhD, Head of Pharmacy Program, Monash University Sunway Campus, Petaling Jaya, Malaysia  
Wilson Low, MSc, Manager, Azmi Burhani Consulting, Petaling Jaya, Malaysia  

Pakistan (1)  
Muhammad Intezar, BSc, Software Engineer, NBSST House, Muridke, Pakistan  

Singapore (2)  
Andrew Eggleston, MSc, RPh, Director, Market Access-Asia, Sanofi, Singapore  
Patrick Tung, BSc, Regional Director, Merck Serono, Singapore  

Sri Lanka (1)  
Devathas Vijitha, PharmD, Secretary, Urban Council Kattankudy, Kattankudy, Sri Lanka  

Thailand (1)  
Nantasit Luangasanatip, MSc, PhD student, Mahidol-Oxford Research Unit (MORU), Bangkok, Thailand  

USA (10)  
Jay Bae, PhD, Researcher, Eli Lilly, Indianapolis, IN, USA  
Chakkarin Burudpakdee, PharmD, Vice President, MKTXS, Raritan, NJ, USA  
Arthi Chandran, MS, MPH, Director, Becton Dikinson, Franklin Lakes, NJ, USA  
Amarpreet Chawla, PhD, Global Life Sciences Consultant, Quintiles Consulting, Durham, NC, USA  
Cyrus Chowdhury, BA, MSc, Chief Executive Officer & Managing Director, CBPartners, New York, NY, USA  
Sandeep Duttagupta, PhD, Vice President, CBPartners, New York, NY, USA  
Ning Yan Gu, PhD, Assistant Professor, University of New Mexico, Albuquerque, NM, USA  
Yi Han, MBA, PhD, SVP Market Access Policy, WG Consulting, New York, NY, USA  
Manpreet Sidhu, MBA, PhD, Director, Oxford Outcomes, Morristown, NJ, USA  
Donald Yin, PhD, Associate Vice President & Head, Global Health Outcomes, Merck, Whitehouse Station, NJ, USA  

ISPOR (4)  
William H. Crown, PhD, 2013-2014 President, ISPOR  
Marilyn Dix Smith, PhD, RPh, ISPOR Founding Executive Director  
Robert Selby, Assistant Manager, ISPOR Asia-Pacific Development  
Zandra Z. Yin, MA, MPA, Director, ISPOR International Development (Asia, Oceania, Africa and Europe)